GSK takes orders for 440 million doses of H1N1 vaccine
This article was originally published in Scrip
GlaxoSmithKline has disclosed that it has so far received worldwide orders for 440 million doses of pandemic influenza A (H1N1) vaccine, an increase of 149 million doses on figures it released in August. However, other key manufacturers of pandemic H1N1 vaccines have not released aggregate figures to date.
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.